Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Obesity Market Insights, Epidemiology & Forecast 2026-2036 | Obesity Market Forecast to Expand at Approximately 27% CAGR Through 2036 as Oral GLP-1 Therapies and Pipeline Innovation Accelerate Growth

globenewswire.com
PFE Pfizer is mentioned as a key company shaping the obesity competitive landscape, indicating its involvement in the market, but no specific product or performance details are provided. RC Roche is developing enicepatide (CT-388), a dual GLP-1/GIP receptor agonist for obesity, with positive Phase II data presented, suggesting strong pipeline potential in the growing obesity market.

Obesity Market Insights, Epidemiology & Forecast 2026-2036 | Obesity Market Forecast to Expand at Approximately 27% CAGR Through 2036 as Oral GLP-1 Therapies and Pipeline Innovation Accelerate Growth Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Obesity - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The global obesity therapeutics market is entering a period of substantial growth, supported by a rising patient burden, wider recognition of obesity as a chronic disease, improved treatment access, and rapid innovation in incretin-based therapies. According to the report, the obesity market across the seven major markets-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-was valued at approximately USD 16 billion in 2025. The market is projected to grow at a compound annual growth rate of approximately 27% from 2022 to 2036.

Key Obesity Market and Epidemiology Insights

Obesity Treatment Landscape and Market Leaders

The obesity treatment landscape is increasingly centered on highly effective incretin-based therapies. Novo Nordisk and Eli Lilly currently lead the branded market through products including WEGOVY (semaglutide), SAXENDA (liraglutide), and ZEPBOUND (tirzepatide). These therapies have established new benchmarks for weight reduction and commercial performance while accelerating investment in oral formulations, dual agonists, and multi-receptor candidates.

Treatment strategies continue to include lifestyle intervention, pharmacotherapy, and bariatric surgery. Available drug classes include GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, pancreatic lipase inhibitors, sympathomimetics, and combination therapies. Established products such as XENICAL (orlistat) and QSYMIA (phentermine/topiramate) are expected to retain roles in selected populations, although newer incretin therapies are anticipated to account for an increasing share of the obesity therapeutics market.

Oral therapies are expected to broaden the addressable patient population by providing alternatives to injectable treatment. Novo Nordisk received US FDA approval for oral semaglutide 25 mg under the WEGOVY brand in December 2025, followed by access initiatives and international expansion. In the United Kingdom, approximately 300,000 patients were estimated to be using oral WEGOVY within three weeks of launch, indicating the potential for oral treatment to attract new patients rather than simply shift existing users away from injections.

Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (FOUNDAYO), received US FDA approval in April 2026 for adults with obesity or overweight and at least one weight-related comorbidity. Its oral administration and positioning for chronic weight management may support rapid uptake during the 2026-2036 forecast period.

Obesity Pipeline and Competitive Outlook

The obesity drug pipeline is expanding beyond established GLP-1 therapies, with investigational programs focused on greater weight reduction, improved durability, better tolerability, and more convenient administration. Notable candidates include enicepatide (CT-388) from Roche and Carmot Therapeutics and RGT-075 from Regor Therapeutics.

Enicepatide is an investigational once-weekly dual GLP-1/GIP receptor agonist being evaluated for obesity and related metabolic conditions. Roche presented Phase II efficacy and safety data for the candidate at the American Diabetes Association's 2026 meeting. Regor Therapeutics reported Phase IIa topline results for RGT-075, an oral once-daily GLP-1 receptor agonist, in January 2025.

Key companies shaping the obesity competitive landscape include Eli Lilly, Novo Nordisk, Currax Pharmaceuticals, Roche, Regor Therapeutics, D&D Pharmatech, and Pfizer. Competition is expected to intensify as developers advance oral agents, longer-acting products, multi-agonist therapies, small molecules, peptides, biologics, and combination regimens.

Unmet Needs, Pricing, and Market Access

Major unmet needs include longer-acting therapies, safer and more effective medications, improved reimbursement, updated treatment guidelines, and broader access to chronic weight-management services. Weekly injections can remain a barrier for some patients, creating a significant commercial opportunity for less frequent dosing and convenient oral options.

Affordability and reimbursement will remain central to long-term adoption. Injectable WEGOVY carries a US list price of approximately USD 1,349 per month, although insurance and cash-pay programs may lower patient costs. ZEPBOUND is available through Lilly's self-pay program at approximately USD 299-449 per month, depending on dose. Oral WEGOVY and FOUNDAYO entered the market with self-pay prices starting at approximately USD 149 per month, with many higher-dose regimens priced between USD 299 and USD 349 per month.

Report Coverage and Strategic Value

The report provides historical and forecast obesity epidemiology, market size, therapy-level revenue, drug uptake, peak patient share, pricing, reimbursement, and competitive intelligence for 2022-2036. It also assesses approved treatments, Phase I-III pipeline assets, regulatory developments, clinical data, patents, collaborations, market access, and country-specific treatment practices across North America, Europe, and Japan.

Additional analysis includes epidemiology-based bottom-up forecasting, patient journey assessment, total addressable market evaluation, SWOT analysis, therapy attribute scoring, and perspectives from more than 10 key opinion leaders and subject-matter experts. These insights support pharmaceutical companies, investors, healthcare providers, and other stakeholders in evaluating obesity market opportunities, prioritizing pipeline assets, planning product launches, and developing evidence-based market access strategies.

With prevalence continuing to rise and oral and next-generation therapies expanding treatment choice, the obesity market outlook through 2036 remains highly positive. Sustained growth will depend on clinical differentiation, durable outcomes, patient adherence, manufacturing capacity, competitive pricing, and broader reimbursement across the seven major markets.

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/20iveh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.